Spero Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Spero Therapeutics, Inc. (SPRO) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $8.83 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-26
- Spero Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $8.83M.
- Spero Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$68.57M, a 369.90% decline from fiscal 2023.
- Spero Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $25.40M.
- Spero Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$46.25M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $8.83M 10-K · filed 2026-03-26 |
| 2024-12-31 | -$68.57M 10-K · filed 2026-03-26 |
| 2023-12-31 | $25.40M 10-K · filed 2025-03-27 |
| 2022-12-31 | -$46.25M 10-K · filed 2024-03-13 |
| 2021-12-31 | -$89.56M 10-K · filed 2023-03-30 |
| 2020-12-31 | -$77.67M 10-K · filed 2022-03-31 |
| 2019-12-31 | -$62.62M 10-K · filed 2021-03-11 |
| 2018-12-31 | -$33.24M 10-K · filed 2020-03-16 |
| 2017-12-31 | -$38.71M 10-K · filed 2019-03-14 |
| 2016-12-31 | -$27.15M 10-K · filed 2019-03-14 |
| 2015-12-31 | -$12.83M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |